Cargando…
Immunological response and overall survival in a subset of advanced renal cell carcinoma patients from a randomized phase 2/3 study of naptumomab estafenatox plus IFN-α versus IFN-α
Naptumomab estafenatox/ABR-217620/ANYARA (Nap) has been evaluated in clinical phase 1 and 2/3 studies. RCC patients in the phase 2/3 trial were randomized 1:1 in an open label study to receive Nap+IFN-α or IFN-α. In this study, we analyzed the UK patients for their immunological response in relation...
Autores principales: | Elkord, Eyad, Burt, Deborah J., Sundstedt, Anette, Nordle, Örjan, Hedlund, Gunnar, Hawkins, Robert E. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4414201/ https://www.ncbi.nlm.nih.gov/pubmed/25669986 |
Ejemplares similares
-
Naptumomab Estafenatox: Targeted Immunotherapy with a Novel Immunotoxin
por: Eisen, Tim, et al.
Publicado: (2014) -
Characteristics of oligodeoxyribonucleotides that induce interferon (IFN)-α in the pig and the phenotype of the IFN-α producing cells
por: Domeika, Kristina, et al.
Publicado: (2004) -
IFNα and IFNγ Impede Marek’s Disease Progression
por: Bertzbach, Luca D., et al.
Publicado: (2019) -
IFN-λ1 with Th17 axis cytokines and IFN-α define different subsets in systemic lupus erythematosus (SLE)
por: Oke, Vilija, et al.
Publicado: (2017) -
Differential regulation of IFNα, IFNβ and IFNε gene expression in human cervical epithelial cells
por: Couret, Jennifer, et al.
Publicado: (2017)